DDInter1042 DDInter1381
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Paliperidone {u} (Compound) resembles {v} (Compound) Risperidone
Paliperidone {u} (Compound) binds {v} (Gene) DRD2
Paliperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Paliperidone {u} (Compound) causes {v} (Side Effect) Skin discolouration
Paliperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Paliperidone (Compound) resembles Risperidone (Compound)
Paliperidone (Compound) binds DRD2 (Gene)
Paliperidone (Compound) palliates schizophrenia (Disease)
Paliperidone (Compound) causes Skin discolouration (Side Effect)
Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Paliperidone may lead to a major life threatening interaction when taken with Metoclopramide
Paliperidone may lead to a major life threatening interaction when taken with Vemurafenib